{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:04:41Z","timestamp":1787943881202,"version":"build-2784847793"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Venetoclax (VEN) in combination with hypomethylating agents has emerged as a pivotal therapy for elderly acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, monocytic AML exhibit greater resistance to VEN-based regimens compared to non-monocytic AML. Identifying exploitable vulnerabilities will mitigate resistance and relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a comprehensive analysis of VEN resistance mechanisms in monocytic AML by integrating bulk AML datasets, single-cell RNA sequencing (scRNA-seq) of AML patient bone marrow and patient-derived xenograft (PDX) models, as well as lipidomic sequencing of induced VEN-resistant cell lines. Additionally, we examined the monocytic markers in VEN-resistant cell lines and assessed VEN sensitivity after knocking down the key sphingolipid metabolism gene\n                      <jats:italic>ASAH1<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Analysis of bulk RNA-seq data revealed elevated expression of sphingolipid metabolism genes in the French-American-British (FAB) M5 subtype, which exhibited poor response to VEN-based treatment. Further analysis of scRNA-seq data showed that monocytic AML cells surviving VEN treatment demonstrated the highest sphingolipid metabolism score, particularly in\n                      <jats:italic>CD14<\/jats:italic>\n                      \u207a\n                      <jats:italic>ITGAX<\/jats:italic>\n                      \u207a monocytic AML cells. Notably, induced VEN-resistant cell lines exhibited significantly increased monocytic markers and differential sphingolipid metabolism profiles compared to parental cells. Among the key regulators of sphingolipid metabolism,\n                      <jats:italic>ASAH1<\/jats:italic>\n                      was upregulated, while SPHK1 was downregulated. Knocking down\n                      <jats:italic>ASAH1<\/jats:italic>\n                      enhanced VEN sensitivity without reducing the expression of monocytic markers CD14\/CD64.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that aberrant sphingolipid metabolism contribute to AML resistance to VEN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15272-9","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T12:25:36Z","timestamp":1763814336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ASAH1-mediated sphingolipid metabolic reprogramming in venetoclax resistance of AML: beyond the monocytic phenotypes"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3203-4588","authenticated-orcid":false,"given":"Lei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenlu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8708-9711","authenticated-orcid":false,"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"15272_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329\u201341. https:\/\/doi.org\/10.1016\/j.stem.2012.12.013.","journal-title":"Cell Stem Cell"},{"key":"15272_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362\u201375. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0609.","journal-title":"Cancer Discov"},{"key":"15272_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"key":"15272_CR4","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106\u201317. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0313.","journal-title":"Cancer Discov"},{"key":"15272_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo6891","volume":"14","author":"GP Sullivan","year":"2022","unstructured":"Sullivan GP, Flanagan L, Rodrigues DA, N\u00ed Chonghaile T. The path to venetoclax resistance is paved with mutations, metabolism, and more. Sci Transl Med. 2022;14:eabo6891. https:\/\/doi.org\/10.1126\/scitranslmed.abo6891.","journal-title":"Sci Transl Med"},{"issue":"12","key":"15272_CR6","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens BM, Jones CL, Pollyea DA, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1(12):1176\u201387. https:\/\/doi.org\/10.1038\/s43018-020-00126-z.","journal-title":"Nat Cancer"},{"key":"15272_CR7","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang H, Nakauchi Y, K\u00f6hnke T, et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020;1:826\u201339. https:\/\/doi.org\/10.1038\/s43018-020-0103-x.","journal-title":"Nat Cancer"},{"key":"15272_CR8","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1182\/blood.2021011094","volume":"141","author":"H Kuusanm\u00e4ki","year":"2023","unstructured":"Kuusanm\u00e4ki H, Dufva O, V\u00e4h\u00e4-Koskela M, et al. Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood. 2023;141:1610\u201325. https:\/\/doi.org\/10.1182\/blood.2021011094.","journal-title":"Blood"},{"key":"15272_CR9","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AGX Zeng","year":"2022","unstructured":"Zeng AGX, Bansal S, Jin L, et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med. 2022;28:1212\u201323. https:\/\/doi.org\/10.1038\/s41591-022-01819-x.","journal-title":"Nat Med"},{"key":"15272_CR10","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1182\/bloodadvances.2021006307","volume":"6","author":"SE Kurtz","year":"2022","unstructured":"Kurtz SE, Eide CA, Kaempf A, et al. Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia. Blood Adv. 2022;6:3062\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2021006307.","journal-title":"Blood Adv"},{"key":"15272_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3324\/haematol.2018.214882","volume":"105","author":"H Kuusanm\u00e4ki","year":"2020","unstructured":"Kuusanm\u00e4ki H, Lepp\u00e4 A-M, P\u00f6l\u00f6nen P, et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 2020;105:708\u201320. https:\/\/doi.org\/10.3324\/haematol.2018.214882.","journal-title":"Haematologica"},{"key":"15272_CR12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, et al. Monocytic subclones confer resistance to Venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10:536\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0710.","journal-title":"Cancer Discov"},{"key":"15272_CR13","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/mc.23600","volume":"62","author":"L Zong","year":"2023","unstructured":"Zong L, Yin M, Kong J, et al. Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients. Mol Carcinog. 2023;62:1572\u201384. https:\/\/doi.org\/10.1002\/mc.23600.","journal-title":"Mol Carcinog"},{"key":"15272_CR14","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00277-024-05646-7","volume":"103","author":"L Zhao","year":"2024","unstructured":"Zhao L, Yang J, Chen M, et al. Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study. Ann Hematol. 2024;103:1197\u2013209. https:\/\/doi.org\/10.1007\/s00277-024-05646-7.","journal-title":"Ann Hematol"},{"key":"15272_CR15","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","volume":"13","author":"S Pei","year":"2023","unstructured":"Pei S, Shelton IT, Gillen AE, et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of Venetoclax-based therapy. Cancer Discov. 2023;13:2032\u201349. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1297.","journal-title":"Cancer Discov"},{"key":"15272_CR16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","volume":"4","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA, Loghavi S, Zeng Z, et al. A phase Ib\/II study of Ivosidenib with Venetoclax\u2009\u00b1\u2009Azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. 2023;4:276\u201393. https:\/\/doi.org\/10.1158\/2643-3230.BCD-22-0205.","journal-title":"Blood Cancer Discov"},{"key":"15272_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrm3772","volume":"15","author":"K Ito","year":"2014","unstructured":"Ito K, Suda T. Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol. 2014;15:243\u201356. https:\/\/doi.org\/10.1038\/nrm3772.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"15272_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrm2329","volume":"9","author":"YA Hannun","year":"2008","unstructured":"Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139\u201350. https:\/\/doi.org\/10.1038\/nrm2329.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"15272_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100950","volume":"55","author":"J Ung","year":"2022","unstructured":"Ung J, Tan S-F, Fox TE, et al. Harnessing the power of sphingolipids: prospects for acute myeloid leukemia. Blood Rev. 2022;55:100950. https:\/\/doi.org\/10.1016\/j.blre.2022.100950.","journal-title":"Blood Rev"},{"key":"15272_CR20","doi-asserted-by":"publisher","first-page":"83208","DOI":"10.18632\/oncotarget.13079","volume":"7","author":"S-F Tan","year":"2016","unstructured":"Tan S-F, Liu X, Fox TE, et al. Acid ceramidase is upregulated in AML and represents a novel therapeutic target. Oncotarget. 2016;7:83208\u201322. https:\/\/doi.org\/10.18632\/oncotarget.13079.","journal-title":"Oncotarget"},{"key":"15272_CR21","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.stem.2019.09.008","volume":"25","author":"SZ Xie","year":"2019","unstructured":"Xie SZ, Garcia-Prat L, Voisin V, et al. Sphingolipid modulation activates proteostasis programs to govern human hematopoietic stem cell Self-Renewal. Cell Stem Cell. 2019;25:639\u2013e6537. https:\/\/doi.org\/10.1016\/j.stem.2019.09.008.","journal-title":"Cell Stem Cell"},{"key":"15272_CR22","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850\u2013e8649. https:\/\/doi.org\/10.1016\/j.ccell.2022.07.002.","journal-title":"Cancer Cell"},{"key":"15272_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bbrc.2023.06.061","volume":"673","author":"J Roh","year":"2023","unstructured":"Roh J, Pak H-K, Jeong S, et al. The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma. Biochem Biophys Res Commun. 2023;673:36\u201343. https:\/\/doi.org\/10.1016\/j.bbrc.2023.06.061.","journal-title":"Biochem Biophys Res Commun"},{"key":"15272_CR24","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de Novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1301689.","journal-title":"N Engl J Med"},{"key":"15272_CR25","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1038\/s41375-019-0402-3","volume":"33","author":"NA McNeer","year":"2019","unstructured":"McNeer NA, Philip J, Geiger H, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. 2019;33:1934\u201343. https:\/\/doi.org\/10.1038\/s41375-019-0402-3.","journal-title":"Leukemia"},{"key":"15272_CR26","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek JT, Johnson WE, Parker HS, et al. The Sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28:882\u20133. https:\/\/doi.org\/10.1093\/bioinformatics\/bts034.","journal-title":"Bioinformatics"},{"key":"15272_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28421-6","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu Z, Liu L, Weng S, et al. Machine learning-based integration develops an immune-derived LncRNA signature for improving outcomes in colorectal cancer. Nat Commun. 2022;13:816. https:\/\/doi.org\/10.1038\/s41467-022-28421-6.","journal-title":"Nat Commun"},{"key":"15272_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559. https:\/\/doi.org\/10.1186\/1471-2105-9-559.","journal-title":"BMC Bioinformatics"},{"key":"15272_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00167-2","volume":"5","author":"S-H Yoon","year":"2021","unstructured":"Yoon S-H, Choi S-W, Nam SW, et al. Preoperative immune landscape predisposes adverse outcomes in hepatocellular carcinoma patients with liver transplantation. NPJ Precis Oncol. 2021;5:27. https:\/\/doi.org\/10.1038\/s41698-021-00167-2.","journal-title":"NPJ Precis Oncol"},{"key":"15272_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, et al. Clusterprofiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2:100141. https:\/\/doi.org\/10.1016\/j.xinn.2021.100141.","journal-title":"Innovation (Camb)"},{"key":"15272_CR31","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","volume":"2","author":"C Bosc","year":"2021","unstructured":"Bosc C, Saland E, Bousard A, et al. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nat Cancer. 2021;2:1204\u201323. https:\/\/doi.org\/10.1038\/s43018-021-00264-y.","journal-title":"Nat Cancer"},{"key":"15272_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s43018-022-00480-0","volume":"4","author":"A Lasry","year":"2023","unstructured":"Lasry A, Nadorp B, Fornerod M, et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023;4:27\u201342. https:\/\/doi.org\/10.1038\/s43018-022-00480-0.","journal-title":"Nat Cancer"},{"key":"15272_CR33","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Millard N, Fan J, et al. Fast, sensitive and accurate integration of single-cell data with harmony. Nat Methods. 2019;16:1289\u201396. https:\/\/doi.org\/10.1038\/s41592-019-0619-0.","journal-title":"Nat Methods"},{"key":"15272_CR34","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen P, Hovestadt V, Wadsworth Ii MH, et al. Single-Cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176:1265\u2013e128124. https:\/\/doi.org\/10.1016\/j.cell.2019.01.031.","journal-title":"Cell"},{"key":"15272_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.aax0249","volume":"367","author":"GS Gulati","year":"2020","unstructured":"Gulati GS, Sikandar SS, Wesche DJ, et al. Single-cell transcriptional diversity is a hallmark of developmental potential. Science. 2020;367:405\u201311. https:\/\/doi.org\/10.1126\/science.aax0249.","journal-title":"Science"},{"key":"15272_CR36","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar S, Gonz\u00e1lez-Blas CB, Moerman T, et al. SCENIC: single-cell regulatory network inference and clustering. Nat Methods. 2017;14:1083\u20136. https:\/\/doi.org\/10.1038\/nmeth.4463.","journal-title":"Nat Methods"},{"key":"15272_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137407","volume":"25","author":"Y Li","year":"2024","unstructured":"Li Y, Sung Y, Choi YE, et al. Synergistic enhancement of antitumor effects by combining abemaciclib with desipramine. Int J Mol Sci. 2024;25:7407. https:\/\/doi.org\/10.3390\/ijms25137407.","journal-title":"Int J Mol Sci"},{"key":"15272_CR38","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","volume":"27","author":"CL Jones","year":"2020","unstructured":"Jones CL, Stevens BM, Pollyea DA, et al. Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells. Cell Stem Cell. 2020;27:748\u2013e7644. https:\/\/doi.org\/10.1016\/j.stem.2020.07.021.","journal-title":"Cell Stem Cell"},{"key":"15272_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752.","journal-title":"Blood"},{"key":"15272_CR40","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.stem.2021.02.013","volume":"28","author":"CL Jones","year":"2021","unstructured":"Jones CL, Inguva A, Jordan CT. Targeting energy metabolism in cancer stem cells: progress and challenges in leukemia and solid tumors. Cell Stem Cell. 2021;28:378\u201393. https:\/\/doi.org\/10.1016\/j.stem.2021.02.013.","journal-title":"Cell Stem Cell"},{"key":"15272_CR41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood.2022018092","volume":"141","author":"SK Mishra","year":"2023","unstructured":"Mishra SK, Millman SE, Zhang L. Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood. 2023;141:1119\u201335. https:\/\/doi.org\/10.1182\/blood.2022018092.","journal-title":"Blood"},{"key":"15272_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/genes15010063","volume":"15","author":"Y Zhai","year":"2023","unstructured":"Zhai Y, Shen H, Wei H. A comprehensive metabolism-related gene signature predicts the survival of patients with acute myeloid leukemia. Genes. 2023;15:63. https:\/\/doi.org\/10.3390\/genes15010063.","journal-title":"Genes"},{"key":"15272_CR43","doi-asserted-by":"publisher","first-page":"1424365","DOI":"10.3389\/fgene.2024.1424365","volume":"15","author":"N Ren","year":"2024","unstructured":"Ren N, Wang J, Li R, et al. Prognostic implications of metabolism-related genes in acute myeloid leukemia. Front Genet. 2024;15:1424365. https:\/\/doi.org\/10.3389\/fgene.2024.1424365.","journal-title":"Front Genet"},{"key":"15272_CR44","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41419-024-06865-6","volume":"15","author":"H Qin","year":"2024","unstructured":"Qin H, Peng M, Cheng J, et al. A novel LGALS1-depended and immune-associated fatty acid metabolism risk model in acute myeloid leukemia stem cells. Cell Death Dis. 2024;15:482. https:\/\/doi.org\/10.1038\/s41419-024-06865-6.","journal-title":"Cell Death Dis"},{"key":"15272_CR45","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/bloodadvances.2020002981","volume":"5","author":"C Lo Presti","year":"2021","unstructured":"Lo Presti C, Fauvelle F, Jacob M-C, et al. The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker. Blood Adv. 2021;5:156\u201366. https:\/\/doi.org\/10.1182\/bloodadvances.2020002981.","journal-title":"Blood Adv"},{"key":"15272_CR46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41420-018-0075-0","volume":"4","author":"AC Lewis","year":"2018","unstructured":"Lewis AC, Wallington-Beddoe CT, Powell JA, Pitson SM. Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies. Cell Death Discov. 2018;4:72. https:\/\/doi.org\/10.1038\/s41420-018-0075-0.","journal-title":"Cell Death Discov"},{"key":"15272_CR47","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/14728222.2017.1322065","volume":"21","author":"S-F Tan","year":"2017","unstructured":"Tan S-F, Pearson JM, Feith DJ, Loughran TP. The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia. Expert Opin Ther Targets. 2017;21:583\u201390. https:\/\/doi.org\/10.1080\/14728222.2017.1322065.","journal-title":"Expert Opin Ther Targets"},{"key":"15272_CR48","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1182\/blood.2021013277","volume":"139","author":"AC Lewis","year":"2022","unstructured":"Lewis AC, Pope VS, Tea MN, et al. Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia. Blood. 2022;139:3737\u201351. https:\/\/doi.org\/10.1182\/blood.2021013277.","journal-title":"Blood"},{"key":"15272_CR49","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1194\/jlr.RA119000251","volume":"60","author":"L-P Kao","year":"2019","unstructured":"Kao L-P, Morad SAF, Davis TS, et al. Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells. J Lipid Res. 2019;60:1590\u2013602. https:\/\/doi.org\/10.1194\/jlr.RA119000251.","journal-title":"J Lipid Res"},{"key":"15272_CR50","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.bbamem.2006.06.016","volume":"1758","author":"C Ricci","year":"2006","unstructured":"Ricci C, Onida F, Ghidoni R. Sphingolipid players in the leukemia arena. Biochim Biophys Acta. 2006;1758:2121\u201332. https:\/\/doi.org\/10.1016\/j.bbamem.2006.06.016.","journal-title":"Biochim Biophys Acta"},{"key":"15272_CR51","doi-asserted-by":"publisher","first-page":"e22514","DOI":"10.1096\/fj.202200765R","volume":"36","author":"AV Khokhlatchev","year":"2022","unstructured":"Khokhlatchev AV, Sharma A, Deering TG, et al. Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia. FASEB J. 2022;36:e22514. https:\/\/doi.org\/10.1096\/fj.202200765R.","journal-title":"FASEB J"},{"key":"15272_CR52","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrm.2017.107","volume":"19","author":"YA Hannun","year":"2018","unstructured":"Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. 2018;19:175\u201391. https:\/\/doi.org\/10.1038\/nrm.2017.107.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"15272_CR53","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1194\/jlr.M091876","volume":"60","author":"S-F Tan","year":"2019","unstructured":"Tan S-F, Dunton W, Liu X, et al. Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-\u03baB-dependent P-glycoprotein upregulation. J Lipid Res. 2019;60:1078\u201386. https:\/\/doi.org\/10.1194\/jlr.M091876.","journal-title":"J Lipid Res"},{"key":"15272_CR54","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/1541-7786.MCR-19-0619","volume":"18","author":"JM Pearson","year":"2020","unstructured":"Pearson JM, Tan S-F, Sharma A, et al. Ceramide analog SACLAC modulates sphingolipid levels and Mcl-1 splicing to induce apoptosis in acute myeloid leukemia. Mol Cancer Res. 2020;18:352\u201363. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0619.","journal-title":"Mol Cancer Res"},{"key":"15272_CR55","doi-asserted-by":"publisher","first-page":"e54525","DOI":"10.1371\/journal.pone.0054525","volume":"8","author":"L Casson","year":"2013","unstructured":"Casson L, Howell L, Mathews LA, et al. Inhibition of ceramide metabolism sensitizes human leukemia cells to Inhibition of BCL2-like proteins. PLoS ONE. 2013;8:e54525. https:\/\/doi.org\/10.1371\/journal.pone.0054525.","journal-title":"PLoS ONE"},{"key":"15272_CR56","doi-asserted-by":"publisher","first-page":"6622","DOI":"10.1074\/jbc.M706115200","volume":"283","author":"LJ Siskind","year":"2008","unstructured":"Siskind LJ, Feinstein L, Yu T, et al. Anti-apoptotic Bcl-2 family proteins disassemble ceramide channels. J Biol Chem. 2008;283:6622\u201330. https:\/\/doi.org\/10.1074\/jbc.M706115200.","journal-title":"J Biol Chem"},{"key":"15272_CR57","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1194\/jlr.M058750","volume":"56","author":"T Zhang","year":"2015","unstructured":"Zhang T, Barclay L, Walensky LD, Saghatelian A. Regulation of mitochondrial ceramide distribution by members of the BCL-2 family. J Lipid Res. 2015;56:1501\u201310. https:\/\/doi.org\/10.1194\/jlr.M058750.","journal-title":"J Lipid Res"},{"key":"15272_CR58","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.cell.2012.01.038","volume":"148","author":"JE Chipuk","year":"2012","unstructured":"Chipuk JE, McStay GP, Bharti A, et al. Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell. 2012;148:988\u20131000. https:\/\/doi.org\/10.1016\/j.cell.2012.01.038.","journal-title":"Cell"},{"key":"15272_CR59","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","volume":"127","author":"MA Anderson","year":"2016","unstructured":"Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127:3215\u201324. https:\/\/doi.org\/10.1182\/blood-2016-01-688796.","journal-title":"Blood"},{"key":"15272_CR60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bbalip.2016.09.019","volume":"1862","author":"MJ Hern\u00e1ndez-Corbacho","year":"2017","unstructured":"Hern\u00e1ndez-Corbacho MJ, Salama MF, Canals D, et al. Sphingolipids in mitochondria. Biochimica et biophysica acta (BBA) -. Mol Cell Biology Lipids. 2017;1862:56\u201368. https:\/\/doi.org\/10.1016\/j.bbalip.2016.09.019.","journal-title":"Mol Cell Biology Lipids"},{"key":"15272_CR61","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.plipres.2016.03.001","volume":"62","author":"S Pyne","year":"2016","unstructured":"Pyne S, Adams DR, Pyne NJ. Sphingosine 1-phosphate and sphingosine kinases in health and disease: recent advances. Prog Lipid Res. 2016;62:93\u2013106. https:\/\/doi.org\/10.1016\/j.plipres.2016.03.001.","journal-title":"Prog Lipid Res"},{"key":"15272_CR62","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","volume":"636","author":"J Sango","year":"2024","unstructured":"Sango J, Carcamo S, Sirenko M, et al. RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature. 2024;636:241\u201350. https:\/\/doi.org\/10.1038\/s41586-024-08137-x.","journal-title":"Nature"},{"key":"15272_CR63","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s13402-023-00808-7","volume":"46","author":"Q Wang","year":"2023","unstructured":"Wang Q, Zhang N, Liu L, et al. Comprehensive analysis of clinical prognostic features and tumor microenvironment landscape of CD11b\u2009+\u2009CD64\u2009+\u2009patients with acute myeloid leukemia. Cell Oncol. 2023;46:1253\u201368. https:\/\/doi.org\/10.1007\/s13402-023-00808-7.","journal-title":"Cell Oncol"},{"key":"15272_CR64","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","volume":"13","author":"A Waclawiczek","year":"2023","unstructured":"Waclawiczek A, Lepp\u00e4 A-M, Renders S, et al. Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to Azacitidine\/Venetoclax. Cancer Discov. 2023;13:1408\u201327. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0939.","journal-title":"Cancer Discov"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15272-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:25:45Z","timestamp":1781616345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15272-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15272"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15272-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not involved in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}